Table of Contents
Published Date: Dec 25, 2025Oct. 2016 saw continual rises in prices of most vitamins in China, especially VA and VE. Thanks to this, most domestic producers announced growth in Q3 financial reports. For instance, Guangji Pharmaceutical realised a YoY growth of 735.98% in net profit, mainly thanks to increased sales of VB2 and VB6 as well as reduced production costs. Zhejiang NHU also recorded a YoY growth of 196.63% in net profit, due to the surges in VA and VE prices.
Meanwhile, the upward price has attracted many producers of vitamins to expand their production. This month, BASF announced its plan to construct a 1,500 t/a VA plant which is projected to be put it into production by 2020. Chinese enterprise Nenter plans to launch a 20,000 t/a VE project and has already signed a supply agreement with US farnesene producer Amyris.
Yet, if too many enterprises starts new production projects, there is also possibility that the vitamin prices will decline as a result of serious oversupply in the market.
The USD/RMB exchange rate in this newsletter is USD1.00=RMB6.7008 on 10 Oct., 2016, sourced from the People's Bank of China. All the prices mentioned in this newsletter will include the VAT, unless otherwise specified.
Published Date: Dec 24, 2025
Please purchase to view
Published Date: Dec 24, 2025 Published Date: Dec 24, 2025 Published Date: Dec 24, 2025 Published Date: Dec 24, 2025
Buy Now
Add to cart
